Please enter exact key words
Human Monoclonal Antibodies Against Glucagon Receptor

for the Treatment of Diabetes and Hyperglycemia

Home / Available Projects / Human Monoclonal Antibodies Against Glucagon Receptor
Drug Name GPCR-targeted Project 014

The glucagon receptor (GCGR) is a 62 kDa peptide activated by glucagon and is a member of the G-protein coupled family of receptors. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP.
A fully human antibody that specifically binds to GCGR is being developed for the treatment of metabolic disorders including hyperglycemia, type 1 and type 2 diabetes mellitus.

Target Glucagon receptor (GCGR)
Drug Modality Monoclonal antibody
Indication Diabetes; Hyperglycemia
Product Category Biologic
Mechanism of Action Glucagon receptor antagonists
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.